LPA (Apo(a)) dsRNA Composition for Specific Gene Silencing

The patent applies local quality by making the antisense strand completely complementary to the target LPA mRNA for maximum inhibition efficacy, while the sense strand is deliberately designed with non-complementary or reduced complementarity to minimize off-target binding. This asymmetric design ensures high specificity: the antisense strand binds tightly to the target sequence (nucleotides 2-18) while the sense strand's mismatched regions prevent spurious binding to non-target mRNAs, thus resolving the contradiction between efficacy and off-target activity.

The patent employs parameter changes by incorporating modified nucleotides (2′-O-methyl, 2′-fluoro) and unlocked nucleic acid (UNA) residues into specific positions of the dsRNA agent. These chemical modifications alter the physical and biochemical parameters of the nucleic acid, enhancing specificity and reducing off-target effects through improved base pairing fidelity and reduced susceptibility to nucleases. The modifications are strategically placed rather than uniform, balancing manufacturing complexity with performance improvement.

The patent uses targeting ligands as intermediary molecules that facilitate the delivery of the dsRNA agent to specific cellular targets, particularly hepatocytes where LPA is produced. The ligand acts as a mediator that binds to receptors on the target cell surface, enabling selective uptake of the dsRNA complex. This intermediary approach improves delivery efficiency and tissue specificity while allowing the core dsRNA structure to remain relatively simple, thus managing the trade-off between complexity and performance.